title: Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins.
abstract: The cellular pathways involved in the impairment of insulin signaling by cellular stress, triggered by the inflammatory cytokine tumor necrosis factor-alpha (TNF) or by translational inhibitors like cycloheximide and anisomycin were studied. Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K). These defects were partially reversed by wortmannin and LY294002, indicating that a PI3K-regulated step is critical for the impairment of insulin signaling by cellular stress. Induction of cellular stress resulted in complex formation between PI3K and ErbB2/ErbB3 and enhanced PI3K activity, implicating ErbB proteins as downstream effectors of stress-induced insulin resistance. Indeed, stimulation of ErbB2/ErbB3 by NDFbeta1, the ErbB3 ligand, inhibited IRS protein tyrosine phosphorylation and recruitment of downstream effectors. Specific inhibitors of the ErbB2 tyrosine kinase abrogated the activation of ErbB2/ErbB3 and in parallel prevented the reduction in IRS protein functions. Taken together, our results suggest a novel mechanism by which cellular stress induces cross-talk between two different signaling pathways. Stress-dependent transactivation of ErbB2/ErbB3 receptors triggers a PI3K cascade that induces serine phosphorylation of IRS proteins culminating in insulin resistance.
authors.affiliation: Institute of Endocrinology, Sheba Medical Center, Tel Hashomer 52601, Israel.
authors.forename: Rina
authors.initials: R
authors.lastname: Hemi
authors.forename: Keren
authors.initials: K
authors.lastname: Paz
authors.forename: Nadine
authors.initials: N
authors.lastname: Wertheim
authors.forename: Avraham
authors.initials: A
authors.lastname: Karasik
authors.forename: Yehiel
authors.initials: Y
authors.lastname: Zick
authors.forename: Hannah
authors.initials: H
authors.lastname: Kanety
mesh_terms: D000841:Anisomycin / Q000494:pharmacology*; D003513:Cycloheximide / Q000494:pharmacology; D018815:Genes, erbB; D018734:Genes, erbB-2; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D055504:Insulin Receptor Substrate Proteins; D007333:Insulin Resistance; D047908:Intracellular Signaling Peptides and Proteins; D020935:MAP Kinase Signaling System; D020890:Neuregulin-1 / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D010750:Phosphoproteins / Q000378:metabolism*; D012694:Serine / Q000378:metabolism*; D013912:Threonine / Q000378:metabolism*; D015533:Transcriptional Activation; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014443:Tyrosine / Q000378:metabolism
chemical_list: C526292:IRS1 protein, human; C526297:IRS2 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D047908:Intracellular Signaling Peptides and Proteins; D020890:Neuregulin-1; D010750:Phosphoproteins; D014409:Tumor Necrosis Factor-alpha; D013912:Threonine; D014443:Tyrosine; D012694:Serine; D000841:Anisomycin; D003513:Cycloheximide; D019869:Phosphatidylinositol 3-Kinases